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The capacity of β cells to expand in response to insulin resistance is 
a critical factor in the development of 
type 2 diabetes. Proliferation of β cells 
is a major component for these adaptive 
responses in animal models. The extra-
cellular signals responsible for β-cell 
expansion include growth factors, such 
as insulin, and nutrients, such as glu-
cose and amino acids. AKT activation is 
one of the important components link-
ing growth signals to the regulation of 
β-cell expansion. Downstream of AKT, 
tuberous sclerosis complex 1 and 2 
(TSC1/2) and mechanistic target of 
rapamycin complex 1 (mTORC1) signal-
ing have emerged as prime candidates in 
this process, because they integrate sig-
nals from growth factors and nutrients. 
Recent studies demonstrate the impor-
tance of mTORC1 signaling in β cells. 
This review will discuss recent advances 
in the understanding of how this path-
way regulates β-cell mass and present 
data on the role of TSC1 in modulation 
of β-cell mass. Herein, we also demon-
strate that deletion of Tsc1 in pancreatic 
β cells results in improved glucose toler-
ance, hyperinsulinemia and expansion of 
β-cell mass that persists with aging.
Introduction
Type 2 diabetes is characterized by defects 
in β-cell expansion and function in condi-
tions of insulin resistance. The extracellu-
lar signals responsible for β-cell expansion 
include growth factors, insulin and nutri-
ents, such as glucose and amino acids. AKT 
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(also known as protein kinase B) signaling 
links growth signals to the regulation of 
β-cell expansion. Downstream of AKT, 
TSC1/2 (tuberous sclerosis complex) and 
mTORC1 (mechanistic target of rapamy-
cin, complex 1) are key players in this pro-
cess, because they integrate signals from 
growth factors and nutrients. mTORC1 
controls growth (cell size), proliferation 
(cell number) and metabolism directly, 
by modulating eukaryotic initiation fac-
tor 4E-binding proteins (4E-BP 1, 2 
and 3) and ribosomal protein S6 kinases 
(S6K 1 and 2), and indirectly, by attenu-
ating AKT signaling via an mTORC1/
S6K-mediated negative feedback loop.1-10 
How TSC/mTOR signaling regulates 
β-cell mass expansion is not completely 
understood. A better understanding of 
how mTORC1 regulates β-cell mass and 
the role of interactions between mTORC1 
and other signaling pathways in this pro-
cess are critical to discovering how β-cell 
mass adapts to insulin resistance and 
autoimmune injury and, ultimately, how 
it impacts diabetes management. In this 
review, we will discuss our current knowl-
edge of the importance of mTORC1 sig-
naling in modulation of β-cell mass and 
function, and we will also present data 
demonstrating the importance of TSC1 
signaling in β cells.
mTOR: The Signaling Network
Upstream of mTORC1. mTOR is a serine/
threonine kinase that is conserved through 
evolution and is essential for cell growth 
and proliferation.11 mTOR constitutes the 
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systemic effects of rapamycin make it dif-
ficult to identify the functions of differ-
ent mTORC1 signaling components in 
various tissues. Recent experiments using 
conditional knockout mice have begun 
to unravel the tissue-specific functions of 
different mTOR signaling components 
(e.g., Raptor and Rictor) and the contri-
bution of these pathways to whole-body 
metabolism.52,53 Adipocyte-specific defi-
cient mice for Raptor exhibit improved 
glucose tolerance, insulin sensitivity and 
resistance to high-fat feeding.52 In contrast, 
mice with a muscle-specific knockout of 
Raptor are glucose-intolerant and display 
downregulation of proteins involved in 
mitochondrial biogenesis (such as Pgc1α) 
and hyperactivation of Akt (due to loss 
of negative feedback).53 Most recently, 
conditional deletion of Raptor in the liver 
uncovered an important role of mTorc1 
in regulation of adaptation to the fast-
ing state due to a defect in ketogenesis,54 
caused by loss of mTORC1-dependent 
Pparα signaling activation.54 While there 
are many studies in Raptor, the role of 
Rictor has been less well-characterized. 
Conditional deletion of Rictor in the mus-
cle has no apparent phenotype.53 In con-
trast, deletion of Rictor in β cells results in 
glucose intolerance caused by a reduction 
in β-cell mass, β-cell proliferation, pan-
creatic insulin content and glucose-stimu-
lated insulin secretion.55 Currently, little is 
known about the importance of Raptor in 
β cells. However, the above observations 
illustrate that the functions of Raptor are 
tissue-specific, and the next challenge will 
be to determine the contribution of this 
complex to glucose homeostasis.
mTORC1 Regulates b-Cell  
Proliferation, Cell Size and Mass
Studies with rapamycin. Rapamycin 
treatment has been shown to have mixed 
effects on insulin secretion, depending on 
the experimental conditions.56-59 The role 
of mTORC1 in β-cell proliferation using 
rapamycin has been explored in multiple 
studies, which have resulted in five impor-
tant observations. (1) Rapamycin treat-
ment blocks β-cell expansion, cell size and 
proliferation induced by an activation of 
AKT in β cells.60 (2) Inhibition of β-cell 
proliferation by rapamycin results from 
including both AMPK-dependent and 
independent pathways.23,33,34
Downstream of mTORC1. Activation 
of mTORC1 signaling leads to transla-
tion initiation, which includes the syn-
thesis of secreted proteins. mTORC1 
controls growth (cell size) and prolifera-
tion (cell number) by modulating mRNA 
translation through phosphorylation of 
4E-BPs and the S6 kinases (Fig. 1).35-38 
The mTORC1-S6K arm regulates mul-
tiple biological processes, including cell 
growth/size, gene transcription, cell sur-
vival, synaptic plasticity and adipocyte 
differentiation.39,40 S6K promotes mRNA 
translation initiation and other steps of 
protein synthesis by phosphorylating an 
array of substrates, including ribosomal S6 
protein, a component of the 40S ribosome, 
and eIF4B,41,42 PDCD4 (programmed 
cell death 4), eEF2K,43 SKAR (S6K1 
Aly/REF-like substrate),44 CCTβ,45 and 
CBP80.45 However, chronic activation 
of S6K negatively regulates IRS1, there-
fore inactivating the PI3K/AKT signal-
ing pathway.1-4,47 Phosphorylation of the 
4E-BPs triggers the release of eIF4E, 
initiating cap-dependent translation.48,49 
This arm of mTORC1 signaling has 
been linked to induction of cell prolifera-
tion independent of the mTORC1-S6K1 
arm.50 Together these substrates down-
stream of mTORC1 play an integral role 
in mRNA translation initiation and pro-
gression, thus controlling the rate of pro-
tein synthesis.
TSC/mTOR Plays a Critical Role  
in Whole-Body Metabolism
mTORC1 is overactive in many organs in 
animal models of obesity and insulin resis-
tance.1,4,5 Additionally, chronic mTORC1 
activation plays an important role in the 
pathogenesis of insulin resistance in states 
of nutrient excess.1,4,8 This effect is medi-
ated by an S6K1-dependent negative feed-
back loop resulting in phosphorylation 
and degradation of IRS1.1-4 Until recently, 
most of the evidence supporting the role 
of mTORC1 in insulin-sensitive tissues 
was derived from the use of rapamycin 
and alterations in insulin sensitivity in 
global S6K and 4E-bp-deficient mice.1,9,51 
However, abnormalities in multiple tis-
sues observed in global knockouts and 
catalytic unit of two distinct complexes, 
mTORC1 and 2,12,13 which both con-
tain mTOR, mLST8 (mammalian lethal 
with SEC13 protein)/GβL (G-protein 
β-protein subunit-like) and Deptor (DEP 
domain-containing mTOR-interacting 
protein) (Fig. 1). mTORC1 constitutes 
the rapamycin-sensitive arm of mTOR 
signaling and contains Raptor (regula-
tory associated protein of mTOR) and 
PRAS40 (proline-rich AKT substrate 
of 40 kDa).14,15 mTORC2 is insensitive 
to rapamycin and also contains Rictor 
(rapamycin in-sensitive companion of 
mTOR), mSIN1 (mammalian stress-
activated MAPK-interacting protein 1) 
and Protor 1/2 (protein observed with 
rictor 1/2).12,13 mTORC2 phosphory-
lates AKT on serine 473, suggesting that 
this pathway could be indirectly linked 
to proliferation.16 mTORC1 activity is 
modulated by multiple upstream signals, 
which include growth factors, amino 
acids, cytokines, energy and cellular 
stressors. mTORC1 is negatively regu-
lated by TSC1 and TSC2 and the small 
G protein RHEB (Ras homolog enriched 
in brain) (Fig. 1). The major function of 
TSC1 is to stabilize TSC2 and prevent 
its ubiquitin-mediated degradation.17,18 
TSC2 phosphorylation and inactiva-
tion by AKT and ERK, among others, 
releases the inhibition of RHEB, leading 
to activation of mTOR.19-24 In contrast, 
phosphorylation and activation of TSC2 
by AMPK and GSK3β inhibits mTOR 
signaling.23,25 Although amino acids are 
important regulators of mTORC1 activ-
ity, the mechanisms responsible for this 
activation are not as well-characterized as 
the regulation by insulin or growth fac-
tors. RAG-GTPases have been identified 
as important regulators of this process by 
transporting mTORC1 to specific cellular 
compartments and facilitating the ability 
of RHEB-GTP to activate mTORC1.26,27 
Ste20-related kinase, MAP4K3 and the 
class III PI3K, mVPS34, have also been 
shown to link amino acid sensing to 
mTORC1.28-30 Stress and hypoxia act to 
limit growth and protein synthesis by 
mechanisms that are incompletely under-
stood but involve HIF-1 and REDD1.31,32 
Finally, reduction in ATP levels in condi-
tions of energy stress suppresses mTORC1 
signaling via several mechanisms, 
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Figure 1. mtOr signaling pathway. mtOr is part of two major complexes, mtOrC1 and mtOrC2. insulin and growth factor receptors induce Pi3K, 
which results in phosphoinositide-dependent kinase-1 (PDK1)-dependent phosphorylation of t308 of aKt. mtOrC1 is negatively regulated by tSC1 
and tSC2 and positively regulated by the small G protein rHeB. akt phosphorylates tSC2 and disrupts the complex of mtOrC1, which inhibits the Gt-
Pase activating function (GaP activity) of the tSC1-tSC2 complex toward rHeB and favors the GtP bound form of rHeB (active). S6K regulates cell size, 
ribosomal biogenesis and protein synthesis. in addition, S6K signaling inhibits insulin signaling by phosphorylation of irS1 and possibly irS2. mtOrC1 
phosphorylates 4e-BP at multiple sites, leading to dissociation of eiF4e and resulting in cap-dependent translation. additional mtOrC1 targets include 
atG1, PParγ, PGC1α and HiF-1. energy depletion and glucose starvation increase the aMP/atP ratio resulting in augmented aMPK activity. amino acid 
activation of mtOrC1 is more complex and not completely understood but several pathways have been proposed (rag GtPases, hvPS34, MaP4K3 and 
rala). Stress condition such as hypoxia can regulate tSC complex through reDD1/2.
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also displayed improved glucose tolerance 
when compared with control (Fig. 2C), 
and this phenotype was also observed in 
older mice (10–12 mo, data not shown). 
In a parallel experiment, we set out to 
determine if concomitant deletion of Tsc2 
in a Tsc1-deleted background has addi-
tional effects in β cells. βTsc1-/-/Tsc2-/- 
(RIP-Cre Tsc1f/f Tsc2f/f) mice showed lower 
basal glucose levels and hyperinsulinemia 
compared with control mice, but the levels 
were not significantly different than those 
observed in βTsc1-/- mice (Fig. 2A and B). 
Interestingly, glucose tolerance was also 
improved in βTsc1-/-/Tsc2-/- mice but not 
significantly different from βTsc1-/- mice 
(Fig. 2C). Evaluation of β-cell morphom-
etry demonstrated that βTsc1-/- mice had 
increased in β-cell mass that was not sig-
nificantly different than that observed 
in βTsc1-/-/Tsc2-/- mice (Fig. 2A and B). 
The results of these experiments demon-
strate that deletion of Tsc1 in β cells has a 
positive impact on β-cell mass expansion, 
insulin levels and glucose tolerance that 
persists with aging. Moreover, these data 
suggest that deletion of both Tsc1 and Tsc2 
does not have an additive effect on glucose 
metabolism and β-cell mass.
How Downstream mTORC1  
Targets Regulate β-Cell Mass 
Expansion
mTORC1 signaling activation has been 
implicated in regulation of β-cell mass, 
although the role of different direct down-
stream targets is unknown. An emerging 
view is that the 4E-BP and S6K signaling 
arms have distinct roles in regulation of 
proliferation, growth and possibly func-
tion.75 However, it is unclear whether 
the effects of activation of the 4E-BP/
eIF pathway in β cells are different than 
those observed following induction of 
S6K signaling.76 Further studies will need 
to be conducted in order to elucidate these 
differences.
4E-BP proteins. The members of 
the 4E-BP family include three paralogs 
(4E-BP 1, 2 and 3) with different tissue 
expression profiles. 4E-BP proteins are 
repressors of the translation initiation 
factor 4E (eIF4E) and therefore inhibit 
protein translation. Phosphorylation of 
4E-BPs at multiple sites by mTORC1 
comes from mice overexpressing Rheb in 
β cells.68 While the effect on cell size has 
been regularly described in these models, 
it is important to note that the effect of 
mTORC1 on β-cell proliferation has not 
been consistently observed in these stud-
ies. It is possible that different experimen-
tal conditions could, in part, explain these 
differences. However, one important con-
clusion derived from these studies is that 
more research is needed to determine the 
mechanisms and signaling components 
downstream of mTORC1 that control 
β-cell mass, proliferation and function.
TSC1. The TSC1/TSC2 complex 
acts as a functional inhibitor of mTOR. 
Studies in human, mice, flies and yeast 
strongly suggest that their gene products 
are interdependent, and that these proteins 
function primarily as a complex.18,69-71 
The role of Tsc1 in β cells was evaluated 
by deletion of Tsc1 specifically in β cells 
using RIP2-Cre mice.72 These mice pre-
sented a complex phenotype, with older 
mice displaying hyperphagia, obesity and 
diabetes due to the activation of mTorc1 in 
RIP2-Cre-expressing hypothalamic neu-
rons.73 However, evaluation of the β-cell 
phenotype prior to the onset of obesity 
and insulin resistance in 4-week-old mice 
showed that Tsc1-deficient mice exhibit 
augmented β-cell hypertrophy, increased 
insulin synthesis and release and conse-
quent hyperinsulinemia. Interestingly, 
this biphasic phenotype observed is similar 
to that observed in mice with conditional 
deletion of Tsc2 in β cells using the same 
RIP2-Cre line.8 Therefore, it remains 
unclear if the disparate β-cell phenotypes 
observed following conditional deletion 
of Tsc1 vs. to Tsc2 are consequences of 
β-cell specific functions of these proteins 
or alterations resulting from the Cre line 
used.
To further examine the consequences 
of conditional deletion of Tsc1 in β cells, 
we crossed Tsc1 floxed mice with a RIP-
Cre line that displays little hypothalamic 
expression (βTsc1-/-).74 Absence of Tsc1 
expression in islets from βTsc1-/- mice 
was demonstrated by immunostaining 
and immunoblotting (data not shown). 
Evaluation of glucose and insulin levels in 
5- to 6-month-old βTsc1-/- mice revealed 
lower random glucose and hyperinsu-
linemia (Fig. 2A and B). βTsc1-/- mice 
alterations in cyclin D2 and D3 levels 
and Cdk4 activity. (3) Rapamycin mod-
ulates cyclin D2 synthesis and stability, 
suggesting that mTORC1 regulates post-
transcriptional modifications of cell cycle 
components in β cells. (4) Rapamycin 
also ameliorates β-cell expansion in a 
model of insulin resistance, suggest-
ing that mTORC1 coordinates β-cell 
adaptation to hyperglycemia and type 
2 diabetes.9 (5) Rapamycin treatment 
results in reduced proliferation in β cells 
in pregnant mice and causes anti-prolif-
erative effects in transplanted rat β cells 
in vivo.61,62 Together, these studies sug-
gest a role of mTORC1 in the regulation 
of β-cell mass and cell cycle and imply 
that mTORC1 can mediate adaptation 
of β cells to insulin resistance. However, 
it is important to note that in vivo stud-
ies designed to reveal the importance of 
mTORC1 using rapamycin are less than 
ideal because of modulation of insulin sen-
sitivity.63,64 In addition, it is now accepted 
that a major limitation of rapamycin for 
in vivo and in vitro studies is the inhibi-
tion of mTORC1 activity toward only 
a subset of mTORC1 substrates.8,9,65-67 
Therefore, inhibiting mTORC1 signal-
ing in vivo by genetic deletion of Raptor 
in β cells will provide new insights into 
the role of this pathway in nutrient- and 
growth factor-dependent regulation of 
β-cell proliferation.
Evidence from Genetic Models
TSC2. The role of mTORC1 in β cells 
has been explored using animal models 
with gain of mTORC1 function. Mice 
with conditional deletion of Tsc2 in β cells 
(βTsc2-/-) exhibit lower glucose levels, 
hyperinsulinemia and improved glucose 
tolerance. These changes are explained 
by increases in β-cell mass, proliferation 
and cell size.7 A separate study demon-
strated that conditional Tsc2 deletion in 
β cells exhibited a similar phenotype, but 
these mice developed diabetes and β-cell 
failure after 40 weeks.8 The differences 
in the phenotype between these reports 
are most likely explained by different 
genetic backgrounds and the RIP-Cre line 
(hypothalamic expression) used. Further 
confirmation of the effect of mTORC1 
activation in increased β-cell mass 
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impaired insulin secretion.87 The β cells 
display a reduced size and decreased tran-
scription of insulin, demonstrating the 
importance of S6K1 in regulating glu-
cose homeostasis as well as cell growth. 
Interestingly, S6K1-deficient mice are 
resistant to age and high-fat diet-induced 
obesity and remain insulin-sensitive due 
to the loss of the negative feedback loop 
from S6K on Irs1 and Irs2. Together, 
these results suggest an in vivo role for 
S6K in desensitizing tissues to insu-
lin,1,3,47 although the significance of this 
feedback regulation on IRS1 has recently 
been questioned.89 In contrast, S6K2-
deficient mice are phenotypically similar 
to the control mice, suggesting that S6K1 
might be more important than S6K2 for 
glucose homeostasis.90 Recent findings 
also demonstrated that S6K is impor-
tant for insulinoma formation induced 
growth, protein translation and prolifera-
tion.85 The activity of S6K1 is regulated 
by both mTORC1 and PDK1, and several 
of its downstream targets have been iden-
tified. S6K1 and S6K2 regulate ribosomal 
protein S6, the eukaryotic initiation fac-
tor 4B (eIF4B), SKAR and eukaryotic 
elongation factor 2 kinase (eEF2K).86 
S6K1- and S6K2-mediated phosphory-
lation is required for full activation and 
subsequent induction of the 40S ribo-
somal protein S6, which can then induce 
cell growth and proliferation. The impor-
tance of S6K signaling in β cells has been 
assessed in genetically modified mouse 
models. S6K1-deficient mice are viable and 
fertile and only present mild phenotypes 
during development because of a com-
pensatory increase in levels of S6K2.87,88 
Additionally, these mice display glucose 
intolerance and hypoinsulinemia with 
leads to dissociation of eIF4E from 4E-BP, 
allowing elF4E binding to eIF4F and 
eIF4G. This complex formation promotes 
the translational machinery of mRNAs 
with high 5'-UTR secondary structures, 
such as those that encode ribosomal pro-
teins, elongation factors and other proteins 
involved in the assembly and function of 
the translational machinery.38,77,78 This 
pathway regulates translation of mRNAs 
that encode important proteins for many 
biological processes, including prolif-
eration. Our most current knowledge on 
the role of these proteins has been based 
on experiments using 4E-BP1-deficient 
cells or mice. The combined disruption 
of 4e-bp1 and 4e-bp2 in mice increased 
their sensitivity to diet-induced obesity by 
accelerated adipogenesis. These animals 
displayed increased insulin resistance 
associated with increased S6K activity and 
impaired Irs2/Akt signaling in periph-
eral tissues. Unfortunately, the specific 
β-cell phenotype of these animals was 
not analyzed.51 Recent studies have also 
revealed an important role for 4E-BP in 
protection against endoplasmic reticu-
lum (ER) stress in β cells. Expression of 
4e-bp1 was increased by direct transcrip-
tional activation of the Eif4e-bp1 gene in 
islets under ER stress in several mouse 
models of diabetes.79 Most importantly, 
islets from 4e-bp1-null mutant mice were 
more susceptible to ER stress-induced 
apoptosis, suggesting that 4E-BP1 could 
be a survival factor for β cells. In vitro 
studies have demonstrated that growth 
factors, such as insulin, and nutrients, 
such as amino acids and glucose, induce 
phosphorylation of 4E-BP1 in islets and 
insulinoma cells.80-83 However, little is 
known about the importance of different 
4E-BPs and the function of these proteins 
on regulation of β-cell proliferation, size, 
survival, mass and function. In summary, 
studies to determine the importance of 
4E-BP1 in β cells have been limited by the 
alteration on insulin sensitivity observed 
in the global knockout model. Our under-
standing of the role of 4E-BP2 in different 
tissues is limited, but this protein is abun-
dant in the brain and is required for learn-
ing and memory, indicating that in tissues 
it has functions independent of 4E-BP1.84
S6K. The ribosomal protein S6 kinase 
(S6K) is described as a regulator of cell 
Figure 2. Metabolic assessment of rip-Cre tsc1 f/f and rip-Cre tsc1f/f, tsc2 f/f. random glucose 
(a) and insulin (B) levels obtained in the same group and age of mice. intraperitoneal glucose 
tolerance tests (iPGtt) (C) were performed on the same group of mice. Measurements were per-
formed on overnight-fasted 5–7-mo-old male control mice or Tsc 1f/f or Tsc1 f/f, Tsc2 f/f mice. Data 
are presented as mean SeM (n > 3). *p < 0.05 when compared with Rip-Cre Tsc1 f/f (solid gray line), 
Rip-Cre Tsc1 f/f Tsc2 f/f (dotted line) and control (solid black line).
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of mTORC1 that mediate growth and 
proliferative functions; (2) how inhi-
bition on IRS/AKT signaling by the 
negative feedback loop regulates β-cell 
expansion; and (3) what is the physi-
ological role of gain of mTORC1 func-
tion in adaptation of β cells to insulin 
resistance. Answers to these questions 
would further our understanding of the 
role of AKT signaling in conjunction 
with mTORC1 signaling mechanisms 
and how β cells adapt to conditions 
of nutrient excess.
Methods
Islet morphometry, β-cell mass and 
metabolic analysis. Paraformaldehyde-
fixed pancreatic tissues were embedded 
in paraffin using standard techniques. 
Sections were deparaffinized, rehydrated 
and incubated with blocking solution. 
Sections were incubated overnight at 4°C 
with antibodies against insulin (Linco 
Research), followed by secondary anti-
bodies conjugated to FITC (Jackson 
Immunoresearch). DAPI-containing 
mounting media (Vector Laboratories) 
was added to the coverslips. β-cell mass 
assessment was performed by point 
counting morphometry from five insu-
lin-stained sections (5 μm) separated by 
200 μm using NIH Image Pro software 
(Media Cybernetics, Inc.).
Metabolic studies—glucose, intra-
peritoneal glucose tolerance test, ELISA. 
Fasting glucose levels were measured after 
an overnight fasting using an AccuChek II 
glucometer (Roche Diagnostics). Fed glu-
cose levels were obtained at the same time 
in the morning of each day. Glucose toler-
ance test was performed by intraperitoneal 
delivery of 2 g/kg glucose to mice after 
12 h fasting. Blood glucose was moni-
tored for 2 h after glucose delivery. Plasma 
insulin levels were measured using mouse 
insulin ELISA kit (ALPCO).
Statistical analysis. All data are repre-
sented as the mean ± SEM from at least 
three independent experiments unless 
otherwise indicated. Data were analyzed 
by Student t-test or ANOVA followed 
by post hoc analysis where appropriate. 
Results were considered statistically sig-
nificant when the p-value was less than 
0.05 (Fig. 3).
adaptive responses of β cells to nutrient 
excess and tentatively explain some of the 
mechanisms involved in glucose toxicity. 
Together, these data suggest that the neg-
ative feedback of S6K on IRS signaling 
can be a major modulator of β-cell mass 
and function in vivo.
How Decreased AKT Signaling  
by mTORC1-Mediated Negative  
Feedback Modulates β-cell Mass
Obesity induced by excess nutrient intake 
leads to the upregulation of mTORC1/
S6K1 signaling in insulin-sensitive tissues, 
including β cells.1,4,8 Current evidence 
suggests that chronic mTORC1 activa-
tion by nutrient excess contributes to obe-
sity by controlling appetite as well as fat 
deposition in white adipose tissue, liver 
and muscle cells.52-54,93 One consequence 
of chronic mTORC1 hyperactivation 
is the induction of an S6K1-dependent 
negative feedback loop, leading to attenu-
ation of AKT signaling in multiple tissues 
and insulin resistance.1-4 It has been pro-
posed that in contrast to classic feedback 
loops, where a threshold is reached before 
inhibition occurs, mTORC1 seems to 
suppress growth factor signaling in a more 
gradual and continual fashion. Therefore, 
it is conceivable that mTORC1 activation 
could play an initial physiological role in 
adaptation of nutrient excess and obesity, 
but chronic and persistent hyperactiva-
tion could lead to development of insulin 
resistance by a negative feedback loop on 
IRS signaling. Thus, it is also possible that 
S6K activation plays a beneficial compen-
satory role by increasing insulin secretion 
during early adaptation of β-cell cells to 
insulin resistance. However, chronic and 
persistent hyperactivation of S6K during 
later stages of adaptation to conditions 
of nutrient excess, such obesity, could 
have detrimental effects by inhibiting 
IRS/AKT signaling and β-cell expan-
sion. How decreased IRS/AKT signaling 
by this feedback loop modulates β-cell 
mass expansion is unclear, but islets from 
S6KCARIP mice showed reduced phos-
phorylation of Bad, Gsk3β and FoxO1, 
suggesting that these proteins could be 
involved.76 Uncertainties still remain as 
to (1) what are the underlying mecha-
nisms and key downstream effector(s) 
by activation of AKT signaling, impli-
cating this kinase in regulation of β-cell 
cell cycle progression.91 Little is known 
about the signaling events downstream 
of S6K. The importance of ribosomal S6 
protein was assessed using knock-in mice 
containing alanine substitutions at all five 
phosphorylatable serine residues of their 
S6 protein.92 These mice exhibit impaired 
glucose tolerance, lower insulin levels and 
increased insulin sensitivity. The pancre-
atic insulin content was reduced in these 
mice but was not associated with altera-
tions in β-cell mass, implying an effect of 
S6 protein on insulin synthesis. The simi-
larity of this phenotype with that of S6K-
deficient mice suggests that ribosomal S6 
protein is a critical substrate in relating 
metabolic signals from S6K.
To study the role of S6K activa-
tion in pancreatic β cells, we developed 
transgenic mice overexpressing a con-
stitutively active form of S6K in β cells 
(S6KCARIP).76 Activation of S6K signaling 
in these mice improves insulin secretion 
in the absence of changes in β-cell mass. 
These findings revealed for the first time 
that activation of S6K induces insulin 
resistance in β cells by feedback inhibi-
tion of IRS signaling. Importantly, these 
studies also demonstrated that S6K regu-
lates IRS2 levels, a major determinant 
of β-cell proliferation and survival. The 
β-cell insulin resistance induced by this 
mechanism had major negative effects on 
cell cycle progression by modulating lev-
els of Cdk2, p27 and p16. Another major 
effect of insulin resistance in this model 
was increased apoptosis due to decreased 
survival signals from AKT. The balance 
between increased cell cycle entry with 
slow progression and enhanced apoptosis 
resulted in lack of β-cell mass expansion. 
Furthermore, these observations under-
score the importance of the S6K-mediated 
negative feedback on IRS1/2 signaling in 
this phenotype and suggest that one of 
the major consequences of chronic expo-
sure of β cells to nutrient overload is the 
development of impaired IRS signal-
ing. In addition, these studies show that 
S6K activation recapitulates the cell size 
but not the proliferative phenotype of 
models with activation of mTORC1 sig-
naling. These findings serve to elucidate 
some of the abnormalities observed in 
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effects of acute treatment with rapamy-
cin are different than those observed with 
chronic exposure. Chronic exposure to 
this agent disrupts the mTORC2 complex 
altering other signaling pathways, such as 
Akt signaling, a major pathway for regu-
lation of β-cell proliferation and survival. 
(2) In contrast to the potent inhibition 
of rapamycin on S6K phosphorylation 
by mTORC1, the inhibitory effect on 
4E-BP signaling is partial and transient. 
All these limitations also apply to in 
vivo observations in transplant patients 
receiving chronic rapamycin treatment. 
Chronic administration of rapamycin has 
been associated with higher incidence of 
diabetes, although the relative contribu-
tion of β-cell dysfunction and insulin 
resistance to this effect is difficult to dis-
sect.63,64 It is possible that the alterations 
in insulin sensitivity could result from the 
signals from growth factors and nutri-
ents,69,100-105 induces controlled growth 
and is rarely associated with malig-
nancy.106,107 The current evidence sup-
ports the concept that mTORC1 is active 
in states of increased insulin demand and 
plays a major role in β-cell expansion and 
proliferation induced by AKT and insulin 
resistance.1,4,5,9,60,68 Most of our knowl-
edge about the role of mTORC1 in β cells 
comes from in vitro experiments using 
insulinoma cells or isolated islets treated 
with rapamycin. However, the different 
doses and duration of incubation makes 
it difficult to draw consistent conclusions. 
In addition, limiting the use of rapamy-
cin to draw conclusions about the role 
of mTORC1 is problematic, and future 
experiments should be complemented 
by genetic approaches. Several lines of 
evidence support this concept: (1) The 
Summary and Further Perspective
Failure of β cells to expand or adapt to 
insulin resistance results in type 2 dia-
betes. β cells adapt to insulin resistance 
mainly by augmenting proliferation, 
although cell size and apoptosis may also 
play a role in this process.94 Therefore, 
finding therapies that increase or replen-
ish β cells through enhanced proliferation 
will delay, prevent or possibly even cure 
diabetes. The IRS2/PI3K/AKT path-
way plays a critical role in the regulation 
of β-cell proliferation and mass in vivo 
and in vitro.6,95-99 A major limitation of 
this kinase for therapeutic benefit is its 
potential to induce oncogenic transfor-
mation. Downstream of AKT, the TSC/
mTORC1 signaling pathway emerges 
as an important candidate to modulate 
β-cell expansion, because it integrates 
Figure 3. representative pancreatic morphology (a) from mice with different genotypes stained for insulin and DaPi. Quantification of β-cell mass 
(B) in 5–7-mo-old mice (n > 3). Data are mean Se ± SeM *p < 0.05.
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